Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma
Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Immunotherapy with immune-checkpoint inhibitors (ICIs) and targeted therapy with BRAF and MEK inhibitors have revolutionized the treatment of melanoma over the past decade. Despite these breakthroughs, the 5-year survival rate of patients with advanced-stage melanoma is at most 50%, emphasizing the need for additional therapeutic strategies. Adopti...
Alternative Titles
Full title
Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2912526642
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2912526642
Other Identifiers
ISSN
1759-4774,1759-4782
E-ISSN
1759-4782
DOI
10.1038/s41571-023-00848-w
